FSD Pharma Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 17.9 million compared to USD 23.61 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.69 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.58 CAD | 0.00% | -9.38% | -51.67% |
Apr. 25 | FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement | MT |
Apr. 08 | FSD Pharma Receives Nasdaq Non-Compliance Notice | MT |
1st Jan change | Capi. | |
---|---|---|
-51.67% | 17.05M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.46% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- HUGE Stock
- News FSD Pharma Inc.
- FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023